This report provides a comprehensive analysis of the global digital therapeutics for psychiatric illnesses market, examining software-driven, evidence-based interventions for treatment, management, and prevention. The study evaluates market dynamics across various applications, including depression, anxiety, and insomnia, while offering detailed regional forecasts for the Americas, APAC, and Europe. By profiling key industry players and analyzing competitive strategies, the research identifies emerging growth opportunities and technological trends shaping the industry's trajectory through 2032.

Market Overview

The global Digital Therapeutics for Psychiatric Illnesses market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate during the forecast period from 2026 to 2032.

Digital Therapeutics for Psychiatric Illnesses are defined as software program-driven, evidence-based interventions utilized for the treatment, management, or prevention of psychiatric illnesses.

Regional Market Analysis

Global Outlook

LPI (LP Information)'s latest research report, titled “Digital Therapeutics for Psychiatric Illnesses Industry Forecast,” examines historical sales and reviews total global Digital Therapeutics for Psychiatric Illnesses sales in 2025. The report provides a comprehensive analysis of projected sales for the period from 2026 through 2032, categorized by region, market sector, and sub-sector. This study offers a detailed analysis of the global industry in US$ millions.

Regional Projections

• United States: The market for Digital Therapeutics for Psychiatric Illnesses is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• China: The market for Digital Therapeutics for Psychiatric Illnesses is estimated to see upward growth from 2025 through 2032, following a steady compound annual growth rate.
• Europe: The market for Digital Therapeutics for Psychiatric Illnesses is expected to expand from 2025 through 2032, characterized by a sustained compound annual growth rate.

Market Segmentation

By Type

• Prevention
• Management
• Treatment

By Application

• Insomnia
• Depression
• Autistic
• Anxiety Disorder
• Schizophrenia
• Other

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Market Dynamics

This Insight Report provides a comprehensive analysis of the global Digital Therapeutics for Psychiatric Illnesses landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, geography, and market size to identify emerging pockets of opportunity. Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, the study offers a nuanced view of the current state and future trajectory of the market.

Furthermore, the report analyzes the strategies of leading global companies, focusing on their Digital Therapeutics for Psychiatric Illnesses portfolios and capabilities, market entry strategies, market positions, and geographic footprints to understand their unique positions in this accelerating global market.

Key Players

The following companies have been profiled based on inputs gathered from primary experts and an analysis of their coverage, product portfolios, and market penetration:

• Pear Therapeutics
• Akili Interactive
• Big Health
• Click Therapeutics
• Orexo
• Limbix
• Cognoa
• Freespira
• Shandong Xindao Artificial Intelligence Technology Co., Ltd.

Market Concentration: In terms of revenue, the two largest global companies occupied a significant portion of the market share in 2025.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Digital Therapeutics for Psychiatric Illnesses Market Size (2021-2032)

    • 2.1.2 Digital Therapeutics for Psychiatric Illnesses Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Digital Therapeutics for Psychiatric Illnesses by Country/Region (2021, 2025 & 2032)

  • 2.2 Digital Therapeutics for Psychiatric Illnesses Segment by Type

    • 2.2.1 Prevention

    • 2.2.2 Management

    • 2.2.3 Treatment

    • 2.2.4 Digital Therapeutics for Psychiatric Illnesses Market Size by Type

      • 2.2.4.1 Digital Therapeutics for Psychiatric Illnesses Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global Digital Therapeutics for Psychiatric Illnesses Market Size Market Share by Type (2021-2026)

  • 2.3 Digital Therapeutics for Psychiatric Illnesses Segment by Application

    • 2.3.1 Insomnia

    • 2.3.2 Depression

    • 2.3.3 Autistic

    • 2.3.4 Anxiety Disorder

    • 2.3.5 Schizophrenia

    • 2.3.6 Other

    • 2.3.7 Digital Therapeutics for Psychiatric Illnesses Market Size by Application

      • 2.3.7.1 Digital Therapeutics for Psychiatric Illnesses Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.7.2 Global Digital Therapeutics for Psychiatric Illnesses Market Size Market Share by Application (2021-2026)

• 3 Digital Therapeutics for Psychiatric Illnesses Market Size by Player

  • 3.1 Digital Therapeutics for Psychiatric Illnesses Market Size Market Share by Player

    • 3.1.1 Global Digital Therapeutics for Psychiatric Illnesses Revenue by Player (2021-2026)

    • 3.1.2 Global Digital Therapeutics for Psychiatric Illnesses Revenue Market Share by Player (2021-2026)

  • 3.2 Global Digital Therapeutics for Psychiatric Illnesses Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Digital Therapeutics for Psychiatric Illnesses by Region

  • 4.1 Digital Therapeutics for Psychiatric Illnesses Market Size by Region (2021-2026)

  • 4.2 Global Digital Therapeutics for Psychiatric Illnesses Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Digital Therapeutics for Psychiatric Illnesses Market Size Growth (2021-2026)

  • 4.4 APAC Digital Therapeutics for Psychiatric Illnesses Market Size Growth (2021-2026)

  • 4.5 Europe Digital Therapeutics for Psychiatric Illnesses Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Digital Therapeutics for Psychiatric Illnesses Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Digital Therapeutics for Psychiatric Illnesses Market Size by Country (2021-2026)

  • 5.2 Americas Digital Therapeutics for Psychiatric Illnesses Market Size by Type (2021-2026)

  • 5.3 Americas Digital Therapeutics for Psychiatric Illnesses Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Digital Therapeutics for Psychiatric Illnesses Market Size by Region (2021-2026)

  • 6.2 APAC Digital Therapeutics for Psychiatric Illnesses Market Size by Type (2021-2026)

  • 6.3 APAC Digital Therapeutics for Psychiatric Illnesses Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Digital Therapeutics for Psychiatric Illnesses Market Size by Country (2021-2026)

  • 7.2 Europe Digital Therapeutics for Psychiatric Illnesses Market Size by Type (2021-2026)

  • 7.3 Europe Digital Therapeutics for Psychiatric Illnesses Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Digital Therapeutics for Psychiatric Illnesses by Region (2021-2026)

  • 8.2 Middle East & Africa Digital Therapeutics for Psychiatric Illnesses Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Digital Therapeutics for Psychiatric Illnesses Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Digital Therapeutics for Psychiatric Illnesses Market Forecast

  • 10.1 Global Digital Therapeutics for Psychiatric Illnesses Forecast by Region (2027-2032)

    • 10.1.1 Global Digital Therapeutics for Psychiatric Illnesses Forecast by Region (2027-2032)

    • 10.1.2 Americas Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.1.3 APAC Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.1.4 Europe Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.1.5 Middle East & Africa Digital Therapeutics for Psychiatric Illnesses Forecast

  • 10.2 Americas Digital Therapeutics for Psychiatric Illnesses Forecast by Country (2027-2032)

    • 10.2.1 United States Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.2.2 Canada Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.2.3 Mexico Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.2.4 Brazil Market Digital Therapeutics for Psychiatric Illnesses Forecast

  • 10.3 APAC Digital Therapeutics for Psychiatric Illnesses Forecast by Region (2027-2032)

    • 10.3.1 China Digital Therapeutics for Psychiatric Illnesses Market Forecast

    • 10.3.2 Japan Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.3.3 Korea Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.3.4 Southeast Asia Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.3.5 India Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.3.6 Australia Market Digital Therapeutics for Psychiatric Illnesses Forecast

  • 10.4 Europe Digital Therapeutics for Psychiatric Illnesses Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.4.2 France Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.4.3 UK Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.4.4 Italy Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.4.5 Russia Market Digital Therapeutics for Psychiatric Illnesses Forecast

  • 10.5 Middle East & Africa Digital Therapeutics for Psychiatric Illnesses Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.5.2 South Africa Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.5.3 Israel Market Digital Therapeutics for Psychiatric Illnesses Forecast

    • 10.5.4 Turkey Market Digital Therapeutics for Psychiatric Illnesses Forecast

  • 10.6 Global Digital Therapeutics for Psychiatric Illnesses Forecast by Type (2027-2032)

  • 10.7 Global Digital Therapeutics for Psychiatric Illnesses Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Digital Therapeutics for Psychiatric Illnesses Forecast

• 11 Key Players Analysis

  • 11.1 Pear Therapeutics

    • 11.1.1 Pear Therapeutics Company Information

    • 11.1.2 Pear Therapeutics Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.1.3 Pear Therapeutics Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Pear Therapeutics Main Business Overview

    • 11.1.5 Pear Therapeutics Latest Developments

  • 11.2 Akili Interactive

    • 11.2.1 Akili Interactive Company Information

    • 11.2.2 Akili Interactive Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.2.3 Akili Interactive Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Akili Interactive Main Business Overview

    • 11.2.5 Akili Interactive Latest Developments

  • 11.3 Big Health

    • 11.3.1 Big Health Company Information

    • 11.3.2 Big Health Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.3.3 Big Health Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Big Health Main Business Overview

    • 11.3.5 Big Health Latest Developments

  • 11.4 Click Therapeutics

    • 11.4.1 Click Therapeutics Company Information

    • 11.4.2 Click Therapeutics Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.4.3 Click Therapeutics Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Click Therapeutics Main Business Overview

    • 11.4.5 Click Therapeutics Latest Developments

  • 11.5 Orexo

    • 11.5.1 Orexo Company Information

    • 11.5.2 Orexo Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.5.3 Orexo Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Orexo Main Business Overview

    • 11.5.5 Orexo Latest Developments

  • 11.6 Limbix

    • 11.6.1 Limbix Company Information

    • 11.6.2 Limbix Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.6.3 Limbix Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Limbix Main Business Overview

    • 11.6.5 Limbix Latest Developments

  • 11.7 Cognoa

    • 11.7.1 Cognoa Company Information

    • 11.7.2 Cognoa Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.7.3 Cognoa Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Cognoa Main Business Overview

    • 11.7.5 Cognoa Latest Developments

  • 11.8 Freespira

    • 11.8.1 Freespira Company Information

    • 11.8.2 Freespira Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.8.3 Freespira Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Freespira Main Business Overview

    • 11.8.5 Freespira Latest Developments

  • 11.9 Shandong Xindao Artificial Intelligence Technology Co., Ltd.

    • 11.9.1 Shandong Xindao Artificial Intelligence Technology Co., Ltd. Company Information

    • 11.9.2 Shandong Xindao Artificial Intelligence Technology Co., Ltd. Digital Therapeutics for Psychiatric Illnesses Product Offered

    • 11.9.3 Shandong Xindao Artificial Intelligence Technology Co., Ltd. Digital Therapeutics for Psychiatric Illnesses Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Shandong Xindao Artificial Intelligence Technology Co., Ltd. Main Business Overview

    • 11.9.5 Shandong Xindao Artificial Intelligence Technology Co., Ltd. Latest Developments

• 12 Research Findings and Conclusion